Chief Medical Officer
Sonnet BioTherapeutics
Dr. Kenney has served as the Chief Medical Officer for Sonnet BioTherapeutics since early 2021. He has more than 20 years experience in translational-stage development of biologics, as well as the commercialization strategy and corporate management of preclinical, clinical-stage and commercialized vaccines and immunotherapies. As President of ClinReg Biologics for the past 6 years, he has provided strategic consulting in clinical and regulatory affairs of biologics, medical monitoring and pharmacovigilance in several capacities. Dr. Kenney most recently served as Chief Development Officer at X-VAX Technology and previously held Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH/NIAID. Dr. Kenney received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.
